Parkinson’s disease drug market is anticipated to grow at a significant CAGR of around 7.9% during the forecast period. Parkinson’s disease is a progressive nervous system disorder that affects the movement of the body, and the symptoms start gradually. In some cases, symptoms start with a barely noticeable tremor in just one hand and go further to affect other parts. According to the Parkinson Foundation, almost one million people are living with PD in the US which is expected to rise to 1.2 million in 2030. Pharmaceutical firms are developing new and improved therapies for Parkinson’s disease therapeutics and other assistive therapeutics which is the prominent factor for the market growth. For instance, in April 2021, Optimus Pharma declared that it has received DCGI approval for its Anti-Parkinson's drug Safinamide. Safinamide is indicated as adjunctive treatment to levodopa/carbidopa in patients with PD experience.

Moreover, the significant FDA approvals to new drugs for the treatment of Parkinson’s disease are contributing to the growth of the global Parkinson’s disease drugs market. For instance, in January 2022, Alembic Pharmaceuticals received final approval from the U.S. Food and Drug Administration (FDA) for its generic version of entacapone as an add-on therapy for treating end-of-dose “wearing off” in Parkinson’s disease. These entacapone tablets are “therapeutically equivalent” to Comtan and treat the motor symptoms experienced by Parkinson’s patients. 

Impact of COVID-19 on the Global Parkinson’s Disease Drug Market

The COVID-19 has impacted the PD patients and they may be at higher risk. The indirect effects of the pandemic are associated with the social distancing measures and disruptions in health care systems and PD clinical trials, which may negatively affect PD patient’s mental health and this may create barriers in controlling their PD symptoms. Although PD is not common as other conditions such as cardiovascular diseases, it affects millions of patients around the world whose care has been affected by the global pandemic.

Segmental Outlook

The global Parkinson’s disease drug market is analysed based on the mechanism of action. Based on it the market is sub-segmented into Dopamine Agonists, Anticholinergic, MAO-B Inhibitors, Amantadine, Carbidopa-levodopa, COMT Inhibitors, and others. The above-mentioned segments can be customized as per the requirements.

Global Parkinson Disease Drug Market Share by Mechanism of Action, 2021 (%)

COMT (Catechol-O-Methyltransferase) Inhibitors segment is anticipated to hold a prominent share in the global Parkinson’s disease Drug Market

Carbidopa-Levodopa therapy is the most effective medication to reduce the symptoms of Parkinson’s disease. However, it has been observed that this medication is not as effective as it is. Therefore, it is important that co-therapeutic agents such as COMT Inhibitors are used with carbidopa-levodopa therapy. The two most common COMT inhibitors used in the treatment of Parkinson’s disease are Comtan (entacapone) and Tasmar (tolcapone).  Both these medications are available in the form of tablets, and they are routinely prescribed in conjunction with carbidopa-levodopa therapy. Furthermore, due to the rapidly aging population, the prevalence of Parkinson’s disease is also expected to grow, which may drive the demand for these drugs. For instance, in Dec, 2021 UCB Biopharma SRL a Belgium company inks $1.6B global partnership with Novartis International AG on Parkinson’s disease.

Regional Outlooks

The global Parkinson disease drug market is further segmented based on geography including North America (the US and Canada), Europe (Italy, Spain, Germany, France, Rest of Europe), Asia Pacific (India, China, Japan, South Korea, Rest of Asia Pacific), and the Rest of the World (Latin America and the Middle East and Africa). 

Global Parkinson Disease Drug Market Growth, by Region 2022-2028

The Asia-Pacific is estimated to hold the major share in the Global Parkinson’s Disease Drug Market

Asia-Pacific is anticipated to exhibit a considerable growth rate in Parkinson’s disease drug market due to the improving healthcare sector and ongoing researchers across the region. India and China are the major markets of Parkinson’s disease drugs that will grow considerably in both countries owing to their advanced healthcare system and research facilities. Also due to the increasing age population in the regions such as China and India are also fueling the Parkinson’s disease drug market. For instance, Feb 2021 Eisai Co Ltd made an announcement of the launch of the Parkinson’s disease treatment Equfina. This is the first launch of Equfina in the Asia region excluding Japan. Equfina is launched for the first time in Asian region excluding Japan. In Asia, Eisai has rights for development and marketing for Safinamide and company is preparing for submission of applications for other regions too.

Market Players Outlook

Some of the players of the Parkinson’s disease drug market include AbbVie Inc., Merck & Co. Inc., Boehringer Ingelheim GmbH, GlaxoSmithKline Plc, Bausch Health Companies Inc., Cipla Inc., Daiichi Sankyo Espha Co., Ltd., and others. The market players are considerably contributing to the market growth by adopting various strategies including new product launches, mergers, and acquisitions, collaborations with the government, to stay competitive in the market. For instance, in Oct 2021 Teva Pharmaceuticals Industries Ltd and MODAG GmbH announce licensing collaboration for Neurodegenerative disease drug candidate.

The report covers

• Market value data analysis of 2022 and forecast to 2028
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global Parkinson’s disease drug market.
• Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market